AUA 2025 special: Dr. Guerrero-Ramos shares first results of SunRISe-1 cohort 4

At the American Urological Association's 2025 Annual Meeting in Las Vegas, Dr. Félix Guerrero-Ramos (ES) presented the first results from cohort 4 of the SunRISe-1 study, assessing TAR-200 monotherapy in patients with Bacillus Calmette-Guérin (BCG) - unresponsive papillary-only high-risk non-muscle-invasive bladder cancer.In this episode, UROONCO BCa chief editor Dr. Benjamin Pradere (FR) interviews Dr. Guerrero-Ramos about the study’s design, a detailed discussion of the results, comparisons with other trials such as BOND-003, and the implications for clinical practice. For more updates on bladder cancer, please visit our educational platform UROONCO BCa.For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.

There are no comments yet.

Please log in to write the first comment.